Intellia Therapeutics, Inc.
NTLA
$12.35
$0.151.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -394.60M | -412.69M | -445.81M | -480.19M | -525.91M |
| Total Depreciation and Amortization | 15.63M | 15.92M | 12.47M | 10.15M | 10.27M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 67.95M | 75.79M | 94.89M | 118.14M | 155.67M |
| Change in Net Operating Assets | -52.13M | -73.75M | -72.21M | -66.67M | -17.18M |
| Cash from Operations | -363.15M | -394.74M | -410.65M | -418.58M | -377.15M |
| Capital Expenditure | -473.00K | -1.13M | -1.98M | -3.23M | -4.01M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.49M | 229.16M | 354.05M | 348.33M | 218.00M |
| Cash from Investing | 200.01M | 228.03M | 352.06M | 345.09M | 213.99M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 165.06M | 131.49M | 131.83M | 99.16M | 125.76M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 165.06M | 131.49M | 131.83M | 99.16M | 125.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.92M | -35.22M | 73.24M | 25.67M | -37.40M |